Abstract: A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.
Type:
Grant
Filed:
July 12, 2018
Date of Patent:
August 6, 2019
Assignees:
National University of Singapore, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille
Abstract: The present invention relates to a compound inducing activation of HLA-E-restricted CD8 T cells and/or NK cells in a human subject, and reducing HIV viral load, such as glatiramer acetate and glatiramer acetate related active substances and products, for use in the treatment of HIV infection. Macaques chronically infected by SIV have been treated with glatiramer acetate. One of the animals had already progressed to the stage of AIDS. We injected 18mg of glatiramer acetate three times per week for only 2 weeks. Surprisingly, a strong impact on viral load was observed in response to the treatment. Viremia decreased by 1 log during glatiramer acetate treatment. Even more surprising was the fact that this decrease persisted after stopping the treatment reaching almost a 2 logs decrease in one animal. This is a major result as compared to cART as stopping cART leads to a rebound of the viral load within days.
Type:
Application
Filed:
March 27, 2019
Publication date:
July 18, 2019
Applicant:
INSTITUT PASTEUR
Inventors:
Nicolas HUOT, Beatrice JACQUELIN, Michaela MULLER-TRUTWIN
Abstract: The present invention provides an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients. This immunoassay involves the covalent and oriented coupling of fusion proteins comprising an AGT enzyme and a viral antigen on an identifiable solid support (e.g. fluorescent microspheres). The thus obtained antigen-coupled microspheres show enhanced capture of specific antibodies as compared to antigen-coupled microspheres produced by standard amine coupling procedures.
Type:
Grant
Filed:
July 19, 2017
Date of Patent:
July 16, 2019
Assignee:
INSTITUT PASTEUR
Inventors:
Jean-Claude Manuguerra, Jessica Vanhomwegen, Philippe Despres, Sylvie Paulous
Abstract: The invention relates to a method for in vitro investigating mitochondrial replication dysfunction in a biological sample removed from a subject susceptible of suffering from physiological ageing or physiopathological conditions related to physiological ageing, or physiopathological ageing or associated symptoms or conditions, in particular premature ageing or accelerated ageing, or of a progeroid syndrome, such as Cockayne syndrome (CS), or neurodegenerative disorders or symptoms thereof, in which the levels of at least one species selected in the group of: POLG1 protein, POLG1 RNA, POLG2 protein, protease(s) which have POLG as a target, in particular serine protease(s) such as HTRA3 protein, HTRA2 protein and, HTRA3 RNA or HTRA2 RNA, or any combination of these species, are investigated.
Type:
Grant
Filed:
February 13, 2015
Date of Patent:
July 2, 2019
Assignees:
INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Abstract: Nitroalkene non-steroidal anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of treating inflammation related conditions.
Type:
Application
Filed:
December 27, 2017
Publication date:
June 27, 2019
Applicants:
Institut Pasteur de Montevideo, Universidad de la República
Inventors:
Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez, Paulina Invernizzi, Mariana Ingold, Lucia Colella
Abstract: The present invention is directed to novel compounds of formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.
Type:
Grant
Filed:
June 11, 2015
Date of Patent:
June 18, 2019
Assignees:
UNIVERSITE DE LILLE 2 DROIT ET SANTE, INSTITUT PASTEUR DE LILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Inventors:
Julie Charton, Benoit Deprez, Florence Leroux, Bart Staels, Anne Muhr-Tailleux, Nathalie Hennuyer, Sophie Lestavel, Manuel Lassalle, Barbara Dubanchet
Abstract: The present invention relates to a compound inducing activation of HLA-E-restricted CD8 T cells and/or NK cells in a human subject, and reducing HIV viral load, such as glatiramer acetate and glatiramer acetate related active substances and products, for use in the treatment of HIV infection. Macaques chronically infected by SIV have been treated with glatiramer acetate. One of the animals had already progressed to the stage of AIDS. We injected 18 mg of glatiramer acetate three times per week for only 2 weeks. Surprisingly, a strong impact on viral load was observed in response to the treatment. Viremia decreased by 1 log during glatiramer acetate treatment. Even more surprising was the fact that this decrease persisted after stopping the treatment reaching almost a 2 logs decrease in one animal. This is a major result as compared to cART as stopping cART leads to a rebound of the viral load within days.
Type:
Grant
Filed:
June 25, 2018
Date of Patent:
June 18, 2019
Assignee:
INSTITUT PASTEUR
Inventors:
Nicolas Huot, Beatrice Jacquelin, Michaela Muller-Trutwin
Abstract: The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection.
Type:
Grant
Filed:
June 22, 2015
Date of Patent:
June 11, 2019
Assignees:
INSTITUT PASTEUR, INSTITUT PASTEUR DU CAMBODGE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Frederic Tangy, Anavaj Shakuntabai, Etienne Simon-Loriere, Claude Roth, Philippe Buchy
Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumor or cancer conditions, and for the preparation of agents or compositions for such treatment.
Type:
Grant
Filed:
January 25, 2018
Date of Patent:
June 11, 2019
Assignees:
CENTRE NATIONAL DE LA RECHERCHE SCENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR, UNIVERSITE DE NANTES
Abstract: The present invention relates to a subunit vaccine platform based on multimeric ribonucleoproteins (RNPs) comprising nucleoproteins of a non-segmented negative-strand ribonucleic acid (RNA) virus as carriers of heterologous polypeptides. The present invention also relates to multimeric RNPs resulting from the assembly of at least 200 fusion proteins with a cellular RNA, or to recombinant yeasts or yeast lysates expressing these multimeric RNPs. It also concerns a process for the preparation of these multimeric RNPs or recombinant yeasts or yeast lysates. In particular, the present invention relates to their use as active ingredient for the in vitro production of an immunogenic composition or in eliciting a protective prophylactic or a therapeutic immune response against said heterologous polypeptide in a host in need thereof. Recombinant yeasts or yeast lysates of the invention can also be used as expression and vector systems for delivery to a host.
Type:
Grant
Filed:
September 17, 2014
Date of Patent:
May 28, 2019
Assignees:
INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DIDEROT—PARIS 7
Inventors:
Monica Sala, Daria Jacob, Frederic Tangy
Abstract: Disclosed is a polypeptide including or consisting of the amino acid sequence SEQ id no:1, for use in the treatment or prevention of an inflammatory disease. It further encompasses a nucleic acid sequence encoding a polypeptide, a vector including a nucleic acid and a host cell including a nucleic acid sequence and/or a vector, for use in the treatment or prevention of an inflammatory disease. Also disclosed is a pharmaceutical composition or a food composition including a polypeptide, a nucleic acid sequence, a vector or a host cell and a pharmaceutically acceptable carrier or a dairy product, for the treatment of inflammatory disease. Additionally, a method for the screening of bacteria having immunomodulatory properties is disclosed.
Type:
Grant
Filed:
July 7, 2015
Date of Patent:
May 14, 2019
Assignees:
INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), INSTITUT PASTEUR DE LILLE (IPL)
Inventors:
Gwenael Jan, Benoit Foligne, Helene Falentin, Stephanie-Marie Deutsch
Abstract: The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of STl31-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes STI31-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs.
Type:
Application
Filed:
April 12, 2017
Publication date:
April 25, 2019
Applicants:
NSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS DIDEROT - PARIS 7, INSTITUT PASTEUR, UNIVERSITÉ PARIS XIII PARIS-NORD
Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
Type:
Application
Filed:
July 24, 2018
Publication date:
April 25, 2019
Applicants:
INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Inventors:
Pierre CHARNEAU, Veronique ZENNOU, Francoise PFLUMIO, Aude SIRVEN, Anne DUBART KUPPERSCHMITT
Abstract: A method and device for locating an emitting source of which measurements of emission propagation at locations different from that of the emitting source can be obtained from those locations, lacking space perception, using a sensor mobile along a self-generated path. After having obtained an emission propagation measurement from the mobile sensor at the mobile sensor location, a free energy variation for moving the sensor from its current location to each of plural possible next locations of the mobile sensor is computed, the free energy being computed as a function of a standardized projected probability field of the location of the diffusing source based on previous emission propagation measurements obtained along the self-generated path. A minimum free energy variation value amongst the computed free energy variations is determined and the location associated with the determined minimum free energy variation is identified as being the next location of the sensor.
Abstract: The invention provides methods for the identification of patients capable of controlling HIV progression, as well as to the identification of an antagonist form of IP-10 associated to HIV progression control and the uses thereof for improving the immunological response of HIV patients.
Type:
Grant
Filed:
October 31, 2016
Date of Patent:
April 9, 2019
Assignees:
INSTITUT PASTEUR, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
Inventors:
Michaela Müller-Trutwin, Mickaël J. Y. Ploquin, Matthew Albert, Yoann Madec, Cécile Goujard, Laurence Meyer
Abstract: The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.
Type:
Grant
Filed:
January 18, 2017
Date of Patent:
March 12, 2019
Assignees:
INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Abstract: The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, the polypeptides presenting a high affinity for the PDZ domain of the human MAST2 protein. The invention also relates to polynucleotides, vectors, lentiviral particles, cells as well as compositions containing the same. The invention is also directed to the use of the polypeptides, polynucleotides, vectors, lentiviral particles, cells and compositions in the treatment and/or prevention of a disease, disorder or condition, which alters the Central Nervous System (CNS) and/or the Peripheral Nervous System (PNS). The invention also concerns molecular signatures of cellular genes to determine the neurosurvival and/or neuroprotection activity of a molecule.
Type:
Grant
Filed:
September 14, 2016
Date of Patent:
March 12, 2019
Assignees:
INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
Inventors:
Christophe Prehaud, Monique Lafon, Nicolas Wolff, Zakir Khan, Elouan Terrien, Sandrine Vitry
Abstract: The application generally relates to the attenuation of a RNA virus or of a clone thereof and involves the alteration of sequence space, more particularly the reduction, of mutational robustness of said RNA virus or clone. The means of the application are more particularly dedicated to the attenuation of an infectious RNA virus or clone, for the production of immunogenic composition or vaccine. More particularly, the means of the application involve the replacement of codon(s) by different codon(s), which is(are) selected to differ by only one nucleotide from a codon STOP, more particularly by different but synonymous codon(s), which is(are) selected to differ by only one nucleotide from a codon STOP.
Type:
Grant
Filed:
January 28, 2016
Date of Patent:
February 19, 2019
Assignee:
INSTITUT PASTEUR
Inventors:
Marco Vignuzzi, Cyril Barbezange, Gonzalo Moratorio